pembrolizumab, combination chemotherapy, ovarian cancer, immunotherapy, tumor immune microenvironment, translational, clinical trial, feasibility
Bayesian adaptive design, efficacy-toxicity tradeoff, data analysis stage, design stage, phi coefficient, sensitivity analysis
immune checkpoint inhibitor, AXL inhibitor, Batiraxcept, platinum-resistant ovarian cancer